INDIANAPOLIS – Scientists at Indiana University School of Medicine and Purdue University have developed a novel way to turn a gene on and off in the brain—a finding that could lead to new therapies for cancers and other genetic diseases.
The interdisciplinary team of neurologists and biological engineers discovered they could use a toolbox of light-sensitive proteins and enzymes, combined with a blue light, to alter the epigenetic state of the gene Ascl1, which acts as a switchboard telling stem cells in the brain what to turn into.
Epigenetics is the study of chemical reactions that activate and deactive parts of the genome, which is the complete set of DNA and hereditary information in an organism. While a person’s genome is the same in every cell, their epigenome responds to environmental factors such as stress, diet and toxins, and therefore can change and trigger diseases, he said.
“The ability to determine the fate of neural stem cells may one day be applied to produce neurons in Down syndrome or to reduce the malignancy of brain tumors,” Dr. Zhou said. “Our research presents one more hope that, if caught in an early stage, these diseases can be reversed in the future.”
Dr. Zhou, co-corresponding author on the study, said the research team’s new epigenetic editing technique is similar to “designing a beacon and a missile to deliver to the cells.”
The ability to locate a precise section of a gene and modify it on command makes all the difference, he said.
“We’ve found that a reaction in a very small number of functional epigenetic codes—three to four out of thousands—can be used to turn a gene on and off,” Dr. Zhou said. “This has greatly scaled down the work, making it possible to design a key to the precise keyhole that opens or closes the door to genes that could cause a disease.”
Dr. Zhou said the research is still in the early stages. The team plans to further study their new technique in mouse brains.
Authors in addition to Dr. Zhou are Joseph Irudayaraj, PhD, a professor of agricultural and biological engineering at Purdue; Chiao-Ling Lo, PhD, a research associate in Dr. Zhou’s lab at IU School of Medicine; and Samrat Roy Choudhury, PhD, a former postdoctoral researcher at Purdue.
Their research was supported by the W.M. Keck Foundation, the National Institutes of Health and the Indiana Clinical and Translational Sciences Institute.